Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01392573 · ClinicalTrials.gov registry record · Phase 3
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 413
- Enrollment target
NCT01392573 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 413 participants.
The verdict
NCT01392573, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 413 participants
- Enrollment target
Study Summary
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide (IDegLira) and insulin degludec (IDeg) in subjects with type 2 diabetes. Subjects continue their pre-trial treatment with metformin throughout the entire trial.
Interventions
- DRUG insulin degludec
- DRUG insulin degludec/liraglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 413 participants |
| Start Date | 2011-11-28 |
| Est. Completion | 2012-10-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01392573
The ClinicalTrials.gov registry entry for NCT01392573 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 413 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which insulin degludec is the first listed.
NCT01392573 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01392573 about?
NCT01392573 is a clinical study titled "A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes". This trial is conducted in Asia, Europe and the United States of America (USA). The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide (IDegLira) and insulin degludec (IDeg) in subjects with type 2 diabetes. Subjects continue their pre-trial treatment with metfor...
What is the current status of trial NCT01392573?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 413 participants. The study started on 2011-11-28. Estimated completion is 2012-10-04.
What interventions are being tested in trial NCT01392573?
The interventions under investigation include: insulin degludec (DRUG), insulin degludec/liraglutide (DRUG).
Who is sponsoring clinical trial NCT01392573?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.